GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of ...

Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease ...

Partnership supports development of tumor-activated glycan-directed ADC designed to improve tumor selectivity NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ ...

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been ...

Comprehensive, up-front full-panel NGS across lung cancer stages is preferred to conserve tissue and avoid sequential testing ...

Objectives This study aims to estimate the prevalence of long-lasting severe fatigue and identify possible risk factors in a 2-year follow-up of patients with predominantly mild-to-moderate SARS-CoV-2 ...

The companies will work together to develop new antibody-based technologies for pathology and other applications.

A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...